General form of registration statement for all companies including face-amount certificate companies

COMMITMENT AND CONTINGENCIES (Details)

v3.5.0.2
COMMITMENT AND CONTINGENCIES (Details)
 3 Months Ended 12 Months Ended
Aug. 01, 2015
USD ($)
Oct. 01, 2014
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2015
USD ($)
May 31, 2016
USD ($)
shares
May 31, 2015
USD ($)
Jul. 20, 2016
USD ($)
Feb. 29, 2016
ft²
a
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Employee-related Liabilities, Current     $ 53,750   $ 267,493 $ 106,250    
Allocated Share-based Compensation Expense     0 $ 27,292 327,500 37,500    
Chief Executive Officer [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Employee-related Liabilities, Current     37,500   250,000 106,250    
Employment Agreement, Term   5 years            
Officers' Compensation   $ 150,000     150,000      
Deferred Compensation Arrangement with Individual, Description   performance bonus equal to 2% of CLS Labs’ annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)            
Share-based Compensation Arrangement by Share-based Payment Award, Description   annual stock options, exercisable at the fair market value of CLS Labs’ common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million            
Due to Officers or Stockholders, Current         250,000 106,250    
Former Officer [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Employee-related Liabilities, Current     16,250   16,290      
Due to Officers or Stockholders, Current         $ 16,290      
Chief Operating Officer [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Employment Agreement, Term 5 years              
Officers' Compensation $ 150,000              
Deferred Compensation Arrangement with Individual, Description performance bonus equal to 2% of the Company’s annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)              
Share-based Compensation Arrangement by Share-based Payment Award, Description annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million              
Chief Operating Officer [Member] | One Time Signing Bonus [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares         250,000      
Allocated Share-based Compensation Expense         $ 327,500      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         1 year      
Building [Member] | Affiliated Entity [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Operating Leases, Rent Expense     $ 44,883 $ 44,461 $ 177,844 $ 0    
Area of Real Estate Property (in Square Feet) | ft²               42,392
Area of Land (in Acres) | a               1.92
Convertible Notes Payable [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Debt Instrument, Face Amount             $ 250,000  
Binder Convertible Notes 3 [Member] | Unpaid Accrued Salary Converted to Convertible Note [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]                
COMMITMENT AND CONTINGENCIES (Details) [Line Items]                
Debt Instrument, Face Amount             $ 250,000